<?xml version="1.0" encoding="UTF-8"?>
<p>An estimation of the cost-effectiveness of a national EV-A71 vaccination has been performed in China 
 <xref rid="B59" ref-type="bibr">
  <sup>59</sup>
 </xref> . It was shown that the vaccination would be cost-saving or cost-effective due to prevention of EV-A71-related morbidity, mortality and use of health services among children aged five or younger, compared to anticipated costs with no vaccination. This finding bodes well for the introduction of a safe and effective EV-A71 vaccine in the near future. In December 2015, the Food and Drug Administration (FDA) of China approved an EV-A71-targeting vaccine 
 <xref rid="B59" ref-type="bibr">
  <sup>59</sup>
 </xref> . In China, inactivated EV-A71 vaccines are now commercially available products.
</p>
